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Hematocrit trial
To the Editor:
We read with interest the report by
Ootaki and associates,1 as well as the
correspondence by Shuhaiber2 in refer-
ence to the article by Habib and col-
leagues.3 Ootaki and coworkers1 applied
a transfusion protocol in which blood
was not transfused during cardiopulmo-
nary bypass unless hematocrit was less
than 15%. They found that patients with a
hematocrit of less than 20% had a higher
lactate level than patients with a higher
hematocrit but imply that this has no
functional significance.
In their critique of the article by Habib
and associates,3 which emphasized the
value of the lowest hematocrit as a predic-
tor of outcome, Shuhaiber2 implied that a
hematocrit of 20% is a useful transfusion
trigger. They also called for a prospective
randomized study of hematocrit, as did
Habib’s group.
At the 2002 meeting of the American
Association for Thoracic Surgery, we pre-
sented the results of a prospective random-
ized trial of 2 hemodilution strategies.4
This study was shut down by the Data and
Safety Monitoring Board of the National
Institutes of Health because of a strongly
positive outcome. Infants who had a mean
hematocrit of 27.8%  3.2% (n  73) had
significantly better motor skills at 1 year of
age relative to patients whose lowest he-
matocrit on bypass was 21.5%  2.9%
(n  74). A significantly greater percent-
age of patients at 1 year of age were clas-
sified as developmentally delayed with re-
spect to motor skills relative to patients
perfused at a higher hematocrit. The lactate
level 1 hour after bypass was significantly
lower with the higher hematocrit.
The findings of our prospective ran-
domized study are consistent with several
previous reports derived from our labo-
ratory work in this area.5-7 Studies using
near-infrared spectroscopy suggest that
acute hemodilution during cardiopulmo-
nary bypass results in cerebral hypoxia. It
is important to remember, before discard-
ing the significance of our clinical trial as
being irrelevant to adults because it was
performed in infants, that the mature
brain is significantly more sensitive to
hypoxic injury than the neonatal and in-
fant brain. Nevertheless, we strongly en-
dorse the call for a prospective random-
ized trial of hematocrit in adults
undergoing cardiopulmonary bypass, in-
cluding sensitive end points such as as-
sessment for cognitive dysfunction. In
the meantime, we strongly recommend
that a hematocrit of at least 25% and
preferably closer to 30% should be used
during cardiopulmonary bypass.
Richard A. Jonas, MD
Department of Cardiovascular Surgery
Children’s National Medical Center
Washington, DC 20010
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Randomized prospective trial for
blood transfusion during adult
cardiopulmonary bypass surgery
To the Editor:
Hemoglobin dilution is an expected physi-
ologic response during cardiopulmonary
bypass (CPB) surgery. Current contro-
versy, however, centers around this ques-
tion: what is a safe hematocrit level during
CPB before the patient sustains less than an
expected outcome? The main reason for the
lack of consensus regarding blood transfu-
sion may stem from the lack of a direct
cause (hematocrit level) and effect (mor-
bidity and mortality) relationship or an as-
sociation or both causality and association.
Although it has been found that low pre-
operative hemoglobin levels are correlated
with poorer outcome,1 it does not mean
that correcting this number will result in
improved outcome. This same argument
holds true for intraoperative hematocrits
with the understanding that new-onset in-
traoperative anemia is reversible and
mainly caused by dilution, whereas preop-
erative anemia is pathologic and mainly
caused by nondilutional processes. Also,
despite understanding the reversibility con-
cept, most decisions of intraoperative
transfusion stem from personal and institu-
tional experience, with no defined dimen-
sions. In May 2004, the National Heart,
Lung, and Blood Institute working group
published an executive summary regarding
future directions in cardiac surgery.2 Cre-
ating a cardiovascular surgery clinical re-
search network was one of the pillars, and
I hope that the working group and the Na-
tional Institutes of Health–sponsored work-
shop for neurocognitive changes after car-
diac surgery will consider this trial an
important direction toward filling an exist-
ing critical gap.
Why Is a Hematocrit Trial Timely?
The patient’s physiologic status must be
the underlying cause for a transfusion, and
the outcome of the transfusion (effect)
must also be considered. The practicing
surgeon, including those in training, is cur-
rently confused with the paradigm of cause
and effect that seems to argue that mortal-
ity is higher among patients with low he-
matocrit (25% in women and 23% in
men3,4) and high hematocrit (34%).5
Randomization is lacking in the adult car-
diac surgery group thus far, despite a clear
benefit of increased hematocrit for neuro-
logic outcome in pediatric heart surgery
(mean intraoperative hematocrit: 27.8% vs
21.5%).6
Moreover, despite the benefit of in-
creased oxygen-carrying capacity with
increased hematocrit, we must be aware
that blood transfusions expose patients to
a variety of potential cellular and hu-
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moral antigens. Conservation of blood
during surgery will always be important
because of the shortages of donor blood,
the risks associated with the use of allo-
genic blood products, and the costs of
these products.
At this stage, the outcome measured
needs to be better studied in a larger group
of patients to determine whether a benefi-
cial effect is achieved when the cause is
simply a new-onset decrease in hematocrit
during CPB that requires the action of
blood transfusion.
How Can We Define the
Dimensions for Safe Intraoperative
Hematocrit Level?
In the context of a study trial, all variables
in a scientific study must be controlled ex-
cept for a single variable that is being stud-
ied. This is an incredible task, but it can be
solved with a national task force among
many regional centers and coordinated in
the most organized fashion. Recruitment of
centers that are indifferent to institutional
experience is key for eliminating bias. The
center with established excellence in surgi-
cal outcome among The Society of Tho-
racic Surgeons risk stratification subgroups
will minimize technically dependent out-
come variables and maximize the weighted
effect of a single variable—hematocrit.
The patient population description should
include elective surgical patients who re-
quire primary or redo CPB coronary, valve,
or both types of surgery; who lack hema-
tologic causes for anemia; who have a
well-defined etiology of disease process;
and who lack prior blood transfusions in
the last 3 months, including a well-defined
level of comorbidity.
Selection of Hematocrits
Given the already available data in the lit-
erature, it is important to chose 2 pathways,
each performed randomly at each collabo-
rating surgical unit, given that neither the
perfusionist nor the surgeon will be
blinded. This will mathematically accom-
modate a range of preoperative hematocrits
to better define absolute and relative risk or
benefit to the population sample after trans-
fusion or not. The 2 pathways are (1) trans-
fusing for hematocrits below a discrete
value (20%, 25%, and 30%) and (2) trans-
fusing for hematocrits when an absolute
difference in CPB hematocrits (5, 10, 15,
and 20 integers) is documented during sur-
gery.
The volume of blood transfused should
be held constant, and 1 unit of allogeneic
blood should be sufficient except in rare
circumstances. Should the next hematocrit
level respond, no further blood transfusion
should be given, yet further transfusion
will be given if levels keep decreasing.
Time from acknowledging the hematocrit
level after the intervention (blood transfu-
sion) will need to be further defined at
discussion committees, among other vari-
ables, especially regarding triggers for pre-
operative CPB, postoperative CPB, and in-
tensive care unit periods with respect to 4
important groups of patients—those with
left ventricular dysfunction, recent myocar-
dial infarction, congestive heart failure, and
incomplete revascularization—because
such groups require a higher hematocrit
level.
A host of other blood product trans-
fusion, perfusion, and operative vari-
ables—including age of blood trans-
fused; priming volume; length of
operation; amount of blood transfusion;
type of blood transfused (eg, leukocyte
depleted, cytomegalovirus status, and al-
logeneic vs predonated autologous
blood); pump run; blood-primed pump;
use of preoperative antiplatelets, antico-
agulants, and antifibrinolytics; duration
of CPB; temperature control (hypother-
mia and normothermia); volume of crys-
talloids and colloids infused and reason
for infusion; and volume of other blood
products infused—will need to be ad-
justed after consultation with a consor-
tium of perfusionists and hematologists
who are experienced in this field.
Also, a similar policy for transfusion
should be adopted after surgery to avoid
the potential influence of postoperative
transfusion on clinical outcome. Outcome,
including neurological outcome and sur-
vival, should be temporally and qualita-
tively documented particularly early after
surgery and several years later.
Overall, there must be a safe range of
hematocrits for each patient in adult and
pediatric patients. Available studies re-
main largely observational and cannot
adjust for the effects of all the confound-
ers. In the interim, conservative use of
blood products in heart surgery is war-
ranted because of the infectious and non-
infectious complications of allogeneic
blood transfusion.
Jeffrey H. Shuhaiber, MD
Department of Surgery
University of Illinois at Chicago
Chicago, IL 60612
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Reply to the Editor:
We would like to thank Dr Jonas for his
comments on our recent article.1 Our study
was a prospective, observational study, and
the patients had an uncomplicated course in
which the criteria for red blood cell trans-
fusion included anemia with a hematocrit
level of less than 15% during bypass and
20% after bypass. Jonas and associates2
conducted a randomized study, and they
concluded that a higher hematocrit strategy
was safe for psychomotor development in
infants. Habib and associates3 retrospec-
tively analyzed the surgical outcomes from
their 6-year experience and concluded that
there was a strong association between se-
verity of hemodilution during cardiopul-
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